ClinicalTrials.gg
RecruitingNCT07011927Updated May 1, 2026

Extra-cochlear Electrode Placement at the Post-auricular Vagus Nerve in Cochlear Implantation

An interventional study of Cochlear Implant and Modified Implant Procedure in Hearing Loss, sponsored by NYU Langone Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hearing Loss by NYU Langone Health — 6 open to participants now, 6 under way, none of them phase 3. Hearing Loss · NYU Langone Health.

Planned enrollment
7th of 10
12 · median 14
Started
2025
the only one that year
No phase
10 of 10
6 open now
Registered
9th of 10
by date

Among the 10 studies in Hearing Loss by NYU Langone Health, this one is the 7th largest by planned enrollment, is the only one that started in 2025, is one of 10 with no phase, and was the 9th registered.

Hearing Loss

797 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.

Browse Hearing Loss studies →

Open to participants now

6 of the 10 studies in Hearing Loss by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 125 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 43 (34%) stop at 75 or younger; 47 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hearing Loss by NYU Langone Health, or all of them as a file.
02

Study summary

This study will evaluate hearing outcomes after cochlear implantation with placement of the ECE1 ground electrode near the post-auricular vagus nerve (Arnold's nerve) to assess non-inferiority with respect to placement under the temporalis muscle.

03

Conditions studied

  • Hearing Loss

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • will be undergoing surgery for a cochlear implant from Cochlear Americas
  • is willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • has history of prior ear surgery, congenital ear malformation, or prior cochlear implantation in the ear to be implanted
  • pregnant, planning to become pregnant, or breastfeeding patients cannot undergo the standard-of-care implantation procedures required for participation in the study.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Patients scheduled for Cochlear Implantation

    The experimental arm will enroll patients over the age of 18 undergoing cochlear implantation involving the placement of ECE1 at the approximate location of Arnold's nerve within the ear canal. In the proposed study, a modification to the surgical approach will be done to place ECE1 near Arnold's nerve, while still using a standard electrode array.

    Device: Cochlear Implant · Device: Modified Implant Procedure

Interventions

  • DeviceCochlear Implant

    Eligible Cochlear Americas devices eligible for inclusion in this study include any Cochlear Americas device that has two ground electrodes.

  • DeviceModified Implant Procedure

    Implant procedure will be modified to place ground electrode (ECE1) near Arnold's nerve.

06

What researchers measure

Primary outcomes

  1. AzBio Sentence Recognition Test Score

    The AzBio Sentence Recognition Test is a clinical tool used to evaluate a person's ability to understand speech in noisy environments. The total score is the percentage of words correctly understood, ranging from 0-100%.

    Time frame: Up to Year 1 post cochlear implant activation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: mario.svirsky@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to mario.svirsky@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jul 2028, 32 months after the start.

Of 197 non-industry interventional studies with no phase under Hearing Loss, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 59. This study's planned 32 months is close to that.

Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 10, 2025
StartActual
Oct 17, 2025
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2028
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07011927
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jun 10, 2025
Start date
Oct 17, 2025
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
May 1, 2026

Study contacts

Nicole Capach
Contact
nicole.capach@nyulangone.org
646-501-6905
J. Thomas Roland, Jr., MD
Contact
j.thomas.rolandjr@nyulangone.org
1-212-263-0460
J. Thomas Roland, Jr., MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion